發(fā)布時(shí)間：2018-03-21 06:04

  本文選題：銀杏葉提取物　切入點(diǎn)：胃癌　出處：《廣西醫(yī)科大學(xué)》2017年碩士論文　論文類型：學(xué)位論文

【摘要】：目的:探討銀杏葉提取物(ginkgo biloba extract,EGb761)對順鉑(cis-Diaminedichloroplatinum)誘導(dǎo)的人胃癌細(xì)胞株SGC-7901及耐藥細(xì)胞株SGC-7901/CDDP增殖和凋亡的影響及其對胃癌細(xì)胞化療耐藥的影響及其機(jī)制。方法:將實(shí)驗(yàn)分為SGC-7901及SGC-7901/CDDP兩大組,采用EGb761、順鉑以及EGb761+順鉑聯(lián)合應(yīng)用處理兩組細(xì)胞,采用四甲基偶氮唑藍(lán)(methyl thiazolyl tetrazolium,MTT)法分別檢測兩種細(xì)胞的增殖活性,流式細(xì)胞儀Annexin V-PE/7AAD雙染法檢測兩組細(xì)胞的凋亡,采用實(shí)時(shí)熒光定量PCR(RT-PCR)方法檢測NIBP、NF-κB P65 m RNA的表達(dá)水平,采用免疫印跡法(Western blot)檢測NIBP、NF-κB P65蛋白的表達(dá)水平。結(jié)果:EGb761和順鉑均對兩種胃癌細(xì)胞的增殖具有顯著的抑制作用,并呈劑量依賴性,但SGC-7901/CDDP細(xì)胞對順鉑的敏感性較SGC-7901細(xì)胞差。EGb761與順鉑聯(lián)合應(yīng)用時(shí)可明顯增強(qiáng)SGC-7901和SGC-7901/CDDP細(xì)胞株對順鉑的敏感性并促進(jìn)細(xì)胞的凋亡。實(shí)時(shí)熒光定量PCR和免疫印跡結(jié)果均顯示SGC-7901/CDDP細(xì)胞株中NIBP和NF-κB p65的表達(dá)量比SGC-7901細(xì)胞株高,EGb761能明顯抑制由順鉑誘導(dǎo)的NIBP和NF-κB p65的表達(dá)。實(shí)時(shí)熒光定量PCR結(jié)果顯示,SGC-7901細(xì)胞株vs SGC-7901/CDDP細(xì)胞株,各組NIBP m RNA相對表達(dá)量(SGC-7901組:空白對照組(1.065±0.039),EGb761組(0.899±0.036),順鉑組(1.444±0.058),EGb761+順鉑組(1.107±0.040);SGC-7901/CDDP組:空白對照組(1.606±0.065),EGb761組(1.363±0.067),順鉑組(2.356±0.092),EGb761+順鉑組(1.780±0.076)),NF-κB p65 m RNA相對表達(dá)量(SGC-7901組:空白對照組(1.115±0.036),EGb761組(0.857±0.087),順鉑組(1.480±0.148),EGb761+順鉑組(1.148±0.056);SGC-7901/CDDP組:空白對照組(1.442±0.025),EGb761組(1.206±0.071),順鉑組(2.619±0.215),EGb761+順鉑組(1.634±0.072)。免疫印跡結(jié)果顯示,SGC-7901細(xì)胞株vs SGC-7901/CDDP細(xì)胞株,NIBP蛋白表達(dá)量:0.324±0.021 vs 0.707±0.037,NF-κB P65蛋白表達(dá)量:0.783±0.029 vs 1.540±0.038);各組NIBP的蛋白表達(dá)(SGC-7901組:空白對照組(0.324±0.021),EGb761組(0.233±0.023),順鉑組(0.590±0.023),EGb761+順鉑組(0.328±0.022);SGC-7901/CDDP組:空白對照組(0.707±0.037),EGb761組(0.591±0.037),順鉑組(0.990±0.037),EGb761+順鉑組(0.725±0.037));NF-κB p65的蛋白表達(dá)(SGC-7901組:空白對照組(0.783±0.029),EGb761組(0.628±0.030),順鉑組(1.138±0.029),EGb761+順鉑組(0.770±0.028);SGC-7901/CDDP組:空白對照組(1.540±0.038),EGb761組(0.865±0.031),順鉑組(1.981±0.030),EGb761+順鉑組(1.508±0.016))。結(jié)論:EGb761具有顯著的化療增敏、逆轉(zhuǎn)胃癌細(xì)胞耐藥的作用,可增強(qiáng)順鉑對胃癌細(xì)胞生長的抑制作用并促進(jìn)細(xì)胞凋亡。其逆轉(zhuǎn)腫瘤細(xì)胞耐藥的作用機(jī)制可能是通過抑制NF-κB通路的活性,減少NIBP和NF-κB p65的表達(dá)而實(shí)現(xiàn)。
[Abstract]:Objective: to investigate the effects of ginkgo biloba extract (EGb761) on the proliferation and apoptosis of human gastric cancer cell line SGC-7901 and drug-resistant cell line SGC-7901/CDDP induced by cisplatin cis-Diaminedichloroplatinum.Methods: the experiment was divided into two groups, SGC-7901 and SGC-7901/CDDP. EGb761, cisplatin and EGb761 cisplatin were used to treat the two groups of cells. The proliferative activity of the two cells was detected by methyl thiazolyl tetrazolium MTT, and the apoptosis of the two groups was detected by Annexin V-PE-7AAD double staining. The expression of NF- 魏 B p65 m RNA was detected by real-time quantitative PCR- PCR and the expression of NF- 魏 B p65 protein was detected by Western blot. And in a dose-dependent manner, However, the sensitivity of SGC-7901/CDDP cells to cisplatin was worse than that of SGC-7901 cells. EGb761 combined with cisplatin could significantly enhance the sensitivity of SGC-7901 and SGC-7901/CDDP cell lines to cisplatin and promote cell apoptosis. Real-time quantitative PCR and Western blotting showed that SGC-7901/CDDP. The expression level of NIBP and NF- 魏 B p65 was significantly higher than that of SGC-7901 cell line, and EGb761 could inhibit the expression of NIBP and NF- 魏 B p65 induced by cisplatin. The results of real-time fluorescence quantitative PCR showed that SGC-7901 cell line vs SGC-7901/CDDP cell line. The relative expression of NIBP m RNA in SGC-7901 group: the blank control group (1.065 鹵0.039) EGb761 group (0.899 鹵0.036), the cisplatin group (1.444 鹵0.058) EGb761 cisplatin group (1.107 鹵0.040) SGC-7901 / CDDP group: the blank control group 1.606 鹵0.065Eb761 group (1.363 鹵0.067), the cisplatin group 2.356 鹵0.092tid EGb761 cisplatin group 1.780 鹵0.0766NF- 魏 B p65m RNA relative expression and the 0.0SGC-7901 group: the blank control group 1.115 鹵366-EGb761 + 0.857 鹵0.057; the control group 1.480 鹵0.1488b761; the control group 1.480 鹵0.148b761; the control group 1.480 鹵0.148b761; the control group 1.480 鹵0.088b761; the control group 1.480 鹵0.148b761; the control group 1.480 鹵0.148b761; the control group 1.480 鹵0.148b761; the control group 1.480 鹵0.148b761; the control group 1.480 鹵0.148b761; The expression of NIBP protein in SGC-7901 / CDDP group (1.148 鹵0.056): blank control group (1.442 鹵0.025), EGb761 group (1.206 鹵0.071), cisplatin group (2.619 鹵0.215), EGb761 cisplatin group (1.634 鹵0.072). Western blot analysis showed that SGC-7901 cell line vs SGC-7901/CDDP cell line expressed NIBP protein: 0.324 鹵0.021 vs 0.707 鹵0.037NF- 魏 B p65 protein expression volume: + 0.783 鹵0.029 vs 1.540 鹵0.0381.The expression of NIBP protein in SGC-7901 group was blank. Control group (0.324 鹵0.021) EGb761 group (0.233 鹵0.023), cisplatin group (0.590 鹵0.023) EGb761 group (0.328 鹵0.022) EGb7901 / CDDP group: blank control group 0.707 鹵0.037 + EGb761 group (0.591 鹵0.037), cisplatin group (0.990 鹵0.037) EGb761 cisplatin group (0.725 鹵0.037) -NFB p65 protein expression group, blank control group (0.783 鹵0.029) EGb761 group (0.628 鹵0.030), cisplatin group 1.138 鹵0.029 EGb761 鹵0.070 鹵0.070 mg 7901DP group: control group (0.783 鹵0.029) EGb761 鹵0.038 鹵0.031 鹵0.031 鹵0.031 鹵0.031 鹵0.031 鹵0.038 鹵0.031 鹵0.038 鹵0.031. Conclusion 1. 981 鹵0. 030% EGb761 Cisplatin group (1.508 鹵0. 016) has significant chemosensitivity, and 1. 981 鹵0. 030% EGb761 Cisplatin group has significant chemosensitivity. Reversing the drug resistance of gastric cancer cells can enhance the inhibitory effect of cisplatin on the growth of gastric cancer cells and promote cell apoptosis. The mechanism of reversing drug resistance in gastric cancer cells may be by inhibiting the activity of NF- 魏 B pathway. To reduce the expression of NIBP and NF- 魏 B p65.
【學(xué)位授予單位】：廣西醫(yī)科大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R735.2

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 文坤明;冷敏;程家平;陳正權(quán);陳奕霖;曾慶良;;姜黃素通過抑制STAT3通路調(diào)控人結(jié)腸癌耐奧沙利鉑細(xì)胞株的耐藥性[J];中國免疫學(xué)雜志;2015年08期

2 黃進(jìn)明;沈阿靈;李瓊瑜;齊飛;洪緋;陳宏偉;褚劍鋒;林久茂;洪振豐;彭軍;;片仔癀調(diào)控ABCC1抑制大腸癌HCT-8/5-FU細(xì)胞藥物外排功能的作用機(jī)制研究[J];福建中醫(yī)藥;2014年06期

3 馬海琳;周小娟;張曉智;汪濤;;β-欖香烯誘導(dǎo)LCC-2細(xì)胞凋亡及逆轉(zhuǎn)TAM耐藥性的機(jī)制[J];現(xiàn)代腫瘤醫(yī)學(xué);2014年09期

4 張萍;;腫瘤干細(xì)胞與化療耐藥[J];口腔頜面外科雜志;2014年04期

5 張峰;陳敬清;岑娟;陳笑鴿;丁秀秀;吳春蕊;;具有高水解穩(wěn)定性的姜黃素類似物的抗多藥耐藥腫瘤作用研究[J];中草藥;2014年12期

6 鄒文斌;李兆申;;中國胃癌發(fā)病率及死亡率研究進(jìn)展[J];中國實(shí)用內(nèi)科雜志;2014年04期

7 袁斐;白鋼鋼;苗筠杰;陳勇;陳建偉;李祥;;中藥逆轉(zhuǎn)腫瘤細(xì)胞多藥耐藥的研究進(jìn)展[J];中草藥;2014年06期

8 陳超;蔡天革;張榮華;楊麗;蔡宇;;6種中藥活性成分對K562/ADM耐藥性逆轉(zhuǎn)及P27和P170蛋白表達(dá)影響[J];中成藥;2014年01期

9 李勇;趙群;檀碧波;范立僑;劉慶偉;焦志凱;趙雪峰;郝英杰;;粉防己堿對人胃癌耐藥細(xì)胞鋅指蛋白139、多藥耐藥基因表達(dá)的影響[J];中國中西醫(yī)結(jié)合雜志;2014年01期

10 毛業(yè)波;劉詩權(quán);譚林;周巧;黃杰安;;EGb761對順鉑和足葉乙甙誘導(dǎo)的胃癌SGC-7901細(xì)胞凋亡的增敏作用[J];世界華人消化雜志;2013年31期

，

本文編號：1642577